Somatostatin receptor molecular imaging in a misdiagnosed gastrinoma case

ABSTRACT

Gastrin-secreting tumors, hypergastrinemia and severe ulcer disease form the trademarks of Zollinger-Ellison syndrome (ZES). We report a case of gastrinoma, in a patient who was misdiagnosed for almost five years. The case emphasizes the special role of functional imaging in the personalized approach to the patient with suggestive symptomatology for NETs. Taking into account that in 80 to 100% of cases of gastroenteropancreatic (GEP) NETs are expressing somatostatin receptors, the functional imaging with radiolabeled somatostatin analogues can be used in order to improve its diagnosis, respectively the treatment of GEP NETs. In the approach to the patient with tremendous digestive symptomatology, physicians from different specialties should evaluate NETs specific markers and then insist on structural-functional complementarity, avoiding the waste of time and high cost of repeated structural investigations. The conclusion of our study is that functional imaging is mandatory in the diagnostic algorithm of gastrinoma.

Keywords: Functional imaging, gastrinoma, hypergastrinemia, neuroendocrine tumors, somatostatin receptor scintigraphy

INTRODUCTION

Zollinger–Ellison syndrome (ZES), first described in 1955, can be sporadic or can appear in the context of a multiple endocrine neoplasia type 1.[1] Gastrin release from gastrinoma is followed by a gastric acid hypersecretion, responsible for ZES.[2] ZES is an association between gastrinoma, hypergastrinemia, and severe ulcer disease, located thrice more frequently in the duodenum than in the pancreas.[3] We present a case of a possible gastrinoma, which was initially misdiagnosed, where functional imaging had a key role in the diagnosis.

CASE REPORT

A 44-years-old male was hospitalized for the evaluation after a long history of unexplained significant weight loss, abdominal pain episodes, diarrhea, and vomiting of more than 4 years. He has no reported family history of malignancy. Medical history included diabetes mellitus diagnosed 4 years ago, abdominal pain syndrome, diarrhea, vomiting, hematemesis, and melena episodes throughout this period, culminating with numerous surgical events (liver abscess and cholecystectomy, repeated perforated duodenal ulcers, and perforated jejunal ulcer treated through segmental enterectomy). In his medical file, four times higher values
of gastrin (481 pg/mL) and 12-fold chromogranin A (CgA) values (1200 ng/mL) were found.

The differential diagnosis of gastrinoma was considered, but repeated structural imaging, did not confirm the presence of a tumor or tumor metastases. The structural imaging investigations (ultrasound, computed tomography [CT] and magnetic resonance imaging [MRI]) revealed hepatomegaly, visible intrahepatic ducts (IHD) in the left lobe of the liver, chronic pancreatitis with an enlarged pancreas, and dilated Wirsung duct (Wd), with peritoneal bursitis. Upper digestive tract endoscopy with biopsy yielded unremarkable results: superficial ulceration and chronic nonspecific duodenitis. The patient underwent a barred esophago-gastro-duodenal scan that revealed thickened gastric folds with polypoid aspect, deformed edematous bulb, and gastroesophageal reflux.

False-positive increased biochemical markers (as presented in discussion) were all excluded from the study.

At the time of presentation, physical examination revealed an ill-looking man with a body mass index of 18 and a 80% Karnofsky scale. Significant laboratory findings included accentuated hepatic cytolysis and increased neuroendocrine tumor (NET) markers compared to the values from 2 years ago: ten times higher values of gastrin (1000 µg/mL) and thirty times higher values of CgA (3005 ng/mL).

The patient imaging assessment started again with the structural imaging evaluation: abdominopelvic CT [Figure 1], MR cholangiopancreatography (MRCP), and MR enterography, which again did not show any evidence of pancreatic tumor. MRCP revealed dilatation of the IHD, a dilated hepatic duct, and an enlarged pancreas with cystic areas. MR-enterography did not reveal any pathological elements at the intestinal level: nonhomogeneous cephalic pancreas aspect suggestive of chronic pancreatitis, a dilated Wd, at the cephalic level.

After exhaustive workup, and with the continuing suspicion of gastrinoma, somatostatin receptor scintigraphy (SRS) was indicated. For an optimal imaging of the abdominal cavity, the patient was prepared using a light diet and a mild laxative starting the evening before. Study design: dynamic scintigraphy (60 images, 1 image/s, 128 × 128 matrix), spot scintigraphy (10 min/image, 256 × 256 matrix), whole-body scintigraphy (matrix 256 × 1024, 6 cm/min bed movement), and single-photon emission computed tomography (SPECT) (128 × 128 matrix, 132 images) were acquired early, 2, 4, and 24 h after 10.57 MBq/kg $^{99m}$Tc-Tektrotyde iv dose. For each hot area, regions of interest were defined, uptake was quantified (counts/pixel), and indices were calculated: $I_1 = Tumor/liver$, $I_2 = Tumor/spleen$, $I_3 = Tumor/lung$, $I_4 = Tumor/right$ thigh. Uptake kinetics [Figure 1] and tumor heterogeneity graphs were analyzed [Figure 2]. We diagnosed a very intense uptake, Krenning scale Grade 4, and limited tumor burden score, with possible pancreatic localization, confirming the presence of somatostatin receptors (SR) and advocating the presence of NET [Figure 1a, c – CT, b, d – SRS and Figure 3]. Our scintigraphic findings, correlated with the higher NET marker values, supported our diagnosis of possible gastrinoma on the pancreas.

**DISCUSSION**

Gastrinoma incidence is 1–3/million population/year, and the delay between first symptoms and diagnosis is about 5 years.[4,5] Increased gastrin and CgA levels alone commonly do not establish the diagnosis of a gastrinoma because high
levels can be usually found in conditions unrelated to NETs, such as chronic atrophic gastritis or proton-pump inhibitor therapy.\[5\] Furthermore, there are other causes of elevated CgA levels, such as reduced kidney function, hypertension, different rheumatoid arthritis, and active inflammatory bowel disease.\[6\]

While clinical and laboratory findings can be suggestive for gastrinomas, structural images (CT and MRI) and functional images (SRS) are required for localization and evaluating of primary tumor and metastases, definitive diagnosis however being established by the pathologist report. Small functional NETs can often pose a diagnostic challenge, and sometimes, multiple imaging modalities are required to locate tumor. In our case, the false-negative image of chronic pancreatitis could be explained by the use of noncontrast MRI because the small lesion would have been visible only in the arterial phase.

SRS, especially SRS-SPECT, with a sensitivity of 78%–88% (87.5% for $^{99m}$Tc hydrazinonicotinyl-Tyr3-Octreotide) and a specificity of 85.7%–97%, has a well-established role in finding subtle functional pancreatic NET that are not seen on structural scans.\[5,7\]

Moreover, different SRS positron emission tomography molecules, such as $^{68}$Ga-DOTA-peptide, with a mechanism of action similar to SRS-SPECT tracers, with a wider and better affinity for SR, could be extremely useful for superior lesion targeting, particularly for tumors with low SR expression, with a range for sensitivity of 74.3%–99.9%.\[8,9\]

Despite the evidence of ulcers, ZES should be considered, principally because of our patient’s history and hypergastrinemia. In this case, there were no imaging data, except for SRS, to support the diagnosis.

The medical practitioners have to be aware of certain signs as well as increased values of NET markers. Special attention must be given to the tumors located in the pancreas, considering their greater potential of malignancy.

**CONCLUSION**

SRS imaging represents a mandatory step in the personalized approach to NET patients. Functional metabolic imaging helped establish the diagnosis of gastrinoma, making curative surgical treatment possible and improving the quality of the patient’s life.

**Declaration of patient consent**

The authors certify that they have obtained all appropriate patient consent forms. In the form the patient(s) has/have given his/her/their consent for his/her/their images and other clinical information to be reported in the journal. The patients understand that their names and initials will not be published and due efforts will be made to conceal their identity, but anonymity cannot be guaranteed.

**Financial support and sponsorship**

Nil.
Conflicts of interest

There are no conflicts of interest.

REFERENCES

1. Guarnotta V, Martini C, Davi MV, Pizza G, Colao A, Faggiano A, et al. The Zollinger-Ellison syndrome: Is there a role for somatostatin analogues in the treatment of the gastrinoma? Endocrine 2018;60:15-27.

2. Metz DC, Cadiot G, Poitras P, Ito T, Jensen RT. Diagnosis of Zollinger-Ellison syndrome in the era of PPIs, faulty gastrin assays, sensitive imaging and limited access to acid secretory testing. Int J Endocr Oncol 2017;4:167-85.

3. Dromain C, Déandréis D, Scoazec JY, Goere D, Ducreux M, Baudin E, et al. Imaging of neuroendocrine tumors of the pancreas. Diagn Interv Imaging 2016;97:1241-57.

4. O’Toole D, Fave GD, Jensen RT. Gastric and duodenal neuroendocrine tumours. Best Pract Res Clin Gastroenterol 2012;26:719-35.

5. Mendelson AH, Donowitz M. Catching the zebra: Clinical pearls and pitfalls for the successful diagnosis of Zollinger-Ellison syndrome. Dig Dis Sci 2017;62:2258-65.

6. Gut P, Czarnywojtek A, Fischbach J, Bączyk M, Ziemnicka K, Wrońska E, et al. Chromogranin A – Unspecific neuroendocrine marker. Clinical utility and potential diagnostic pitfalls. Arch Med Sci 2016;12:1-9.

7. Shinto AS, Kamleshwaran K, Vyshak K, Sudhakar N, Banerjee S, Korde A, et al. Clinical utility of indigenously formulated single-vial lyophilized HYNIC-TOC kit in evaluating Gastro-entero Pancreatic neuroendocrine tumours. Asia Ocean J Nucl Med Biol 2014;2:30-41.

8. Pauwels E, Cleeren F, Bormans G, Deroose CM. Somatostatin receptor PET ligands—the next generation for clinical practice. Am J Nucl Mol Imaging 2018;8:311-31.

9. Al Bulushi N, Al Suqri B, Al Aamri M, Al Hadidi A, Al Jahdami H, Al Zadjali M, et al. Diagnostic accuracy of technetium-99m-octreotide in imaging neuroendocrine tumors, Oman hospital experience with literature review. World J Nucl Med 2019;18:137-42.